Review



mt3 boj  (DSMZ)


Bioz Verified Symbol DSMZ is a verified supplier  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 92
      Buy from Supplier

    Structured Review

    DSMZ mt3 boj
    Figure 2. SLC13A3 diminishes tumor immunogenicity (A and B) Tumor growth curves (A), and representative tumor images (B) of Slc13a3+/+ and Slc13a3/ Yumm5.2 tumors in C57BL/6 mice (n = 4–5). Two-way ANOVA, ****p < 0.0001. (C and D) Tumor growth curves (C), and representative tumor images (D) of Slc13a3+/+ and Slc13a3/ B16-F10 tumors in C57BL/6 mice (n = 6–8). Two-way ANOVA, ****p < 0.0001. (E and F) Tumor growth curves (E) and tumor images (F) of Slc13a3+/+, Slc13a3/ <t>MT3</t> tumors in C57BL/6 mice (n = 10). Two-way ANOVA, ****p < 0.0001. (G and H) Percentages of IFNg+ CD8 T cells (G) and TNFa+ CD4 T cells (H) in parental or Slc13a3/ Yumm5.2 tumors, detected by FACS (n = 3). Two-tailed t test, *p < 0.05. (I and J) Tumor growth curves (I), and representative tumor images (J) of Slc13a3+/+ and Slc13a3/ B16-F10 tumors in NSG mice (n = 10–12). All data are presented as mean ± SEM. See also Figure S2.
    Mt3 Boj, supplied by DSMZ, used in various techniques. Bioz Stars score: 92/100, based on 13 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mt3+boj/pm39515327-487-289-310?v=DSMZ
    Average 92 stars, based on 13 article reviews
    mt3 boj - by Bioz Stars, 2026-07
    92/100 stars

    Images

    1) Product Images from "Itaconate transporter SLC13A3 impairs tumor immunity via endowing ferroptosis resistance."

    Article Title: Itaconate transporter SLC13A3 impairs tumor immunity via endowing ferroptosis resistance.

    Journal: Cancer cell

    doi: 10.1016/j.ccell.2024.10.010

    Figure 2. SLC13A3 diminishes tumor immunogenicity (A and B) Tumor growth curves (A), and representative tumor images (B) of Slc13a3+/+ and Slc13a3/ Yumm5.2 tumors in C57BL/6 mice (n = 4–5). Two-way ANOVA, ****p < 0.0001. (C and D) Tumor growth curves (C), and representative tumor images (D) of Slc13a3+/+ and Slc13a3/ B16-F10 tumors in C57BL/6 mice (n = 6–8). Two-way ANOVA, ****p < 0.0001. (E and F) Tumor growth curves (E) and tumor images (F) of Slc13a3+/+, Slc13a3/ MT3 tumors in C57BL/6 mice (n = 10). Two-way ANOVA, ****p < 0.0001. (G and H) Percentages of IFNg+ CD8 T cells (G) and TNFa+ CD4 T cells (H) in parental or Slc13a3/ Yumm5.2 tumors, detected by FACS (n = 3). Two-tailed t test, *p < 0.05. (I and J) Tumor growth curves (I), and representative tumor images (J) of Slc13a3+/+ and Slc13a3/ B16-F10 tumors in NSG mice (n = 10–12). All data are presented as mean ± SEM. See also Figure S2.
    Figure Legend Snippet: Figure 2. SLC13A3 diminishes tumor immunogenicity (A and B) Tumor growth curves (A), and representative tumor images (B) of Slc13a3+/+ and Slc13a3/ Yumm5.2 tumors in C57BL/6 mice (n = 4–5). Two-way ANOVA, ****p < 0.0001. (C and D) Tumor growth curves (C), and representative tumor images (D) of Slc13a3+/+ and Slc13a3/ B16-F10 tumors in C57BL/6 mice (n = 6–8). Two-way ANOVA, ****p < 0.0001. (E and F) Tumor growth curves (E) and tumor images (F) of Slc13a3+/+, Slc13a3/ MT3 tumors in C57BL/6 mice (n = 10). Two-way ANOVA, ****p < 0.0001. (G and H) Percentages of IFNg+ CD8 T cells (G) and TNFa+ CD4 T cells (H) in parental or Slc13a3/ Yumm5.2 tumors, detected by FACS (n = 3). Two-tailed t test, *p < 0.05. (I and J) Tumor growth curves (I), and representative tumor images (J) of Slc13a3+/+ and Slc13a3/ B16-F10 tumors in NSG mice (n = 10–12). All data are presented as mean ± SEM. See also Figure S2.

    Techniques Used: Immunopeptidomics, Two Tailed Test



    Similar Products

    mt3 boj  (DSMZ)
    92
    DSMZ mt3 boj
    Figure 2. SLC13A3 diminishes tumor immunogenicity (A and B) Tumor growth curves (A), and representative tumor images (B) of Slc13a3+/+ and Slc13a3/ Yumm5.2 tumors in C57BL/6 mice (n = 4–5). Two-way ANOVA, ****p < 0.0001. (C and D) Tumor growth curves (C), and representative tumor images (D) of Slc13a3+/+ and Slc13a3/ B16-F10 tumors in C57BL/6 mice (n = 6–8). Two-way ANOVA, ****p < 0.0001. (E and F) Tumor growth curves (E) and tumor images (F) of Slc13a3+/+, Slc13a3/ <t>MT3</t> tumors in C57BL/6 mice (n = 10). Two-way ANOVA, ****p < 0.0001. (G and H) Percentages of IFNg+ CD8 T cells (G) and TNFa+ CD4 T cells (H) in parental or Slc13a3/ Yumm5.2 tumors, detected by FACS (n = 3). Two-tailed t test, *p < 0.05. (I and J) Tumor growth curves (I), and representative tumor images (J) of Slc13a3+/+ and Slc13a3/ B16-F10 tumors in NSG mice (n = 10–12). All data are presented as mean ± SEM. See also Figure S2.
    Mt3 Boj, supplied by DSMZ, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mt3+boj/pm39515327-487-289-310?v=DSMZ
    Average 92 stars, based on 1 article reviews
    mt3 boj - by Bioz Stars, 2026-07
    92/100 stars
    		  Buy from Supplier

    Image Search Results


    Figure 2. SLC13A3 diminishes tumor immunogenicity (A and B) Tumor growth curves (A), and representative tumor images (B) of Slc13a3+/+ and Slc13a3/ Yumm5.2 tumors in C57BL/6 mice (n = 4–5). Two-way ANOVA, ****p < 0.0001. (C and D) Tumor growth curves (C), and representative tumor images (D) of Slc13a3+/+ and Slc13a3/ B16-F10 tumors in C57BL/6 mice (n = 6–8). Two-way ANOVA, ****p < 0.0001. (E and F) Tumor growth curves (E) and tumor images (F) of Slc13a3+/+, Slc13a3/ MT3 tumors in C57BL/6 mice (n = 10). Two-way ANOVA, ****p < 0.0001. (G and H) Percentages of IFNg+ CD8 T cells (G) and TNFa+ CD4 T cells (H) in parental or Slc13a3/ Yumm5.2 tumors, detected by FACS (n = 3). Two-tailed t test, *p < 0.05. (I and J) Tumor growth curves (I), and representative tumor images (J) of Slc13a3+/+ and Slc13a3/ B16-F10 tumors in NSG mice (n = 10–12). All data are presented as mean ± SEM. See also Figure S2.

    Journal: Cancer cell

    Article Title: Itaconate transporter SLC13A3 impairs tumor immunity via endowing ferroptosis resistance.

    doi: 10.1016/j.ccell.2024.10.010

    Figure Lengend Snippet: Figure 2. SLC13A3 diminishes tumor immunogenicity (A and B) Tumor growth curves (A), and representative tumor images (B) of Slc13a3+/+ and Slc13a3/ Yumm5.2 tumors in C57BL/6 mice (n = 4–5). Two-way ANOVA, ****p < 0.0001. (C and D) Tumor growth curves (C), and representative tumor images (D) of Slc13a3+/+ and Slc13a3/ B16-F10 tumors in C57BL/6 mice (n = 6–8). Two-way ANOVA, ****p < 0.0001. (E and F) Tumor growth curves (E) and tumor images (F) of Slc13a3+/+, Slc13a3/ MT3 tumors in C57BL/6 mice (n = 10). Two-way ANOVA, ****p < 0.0001. (G and H) Percentages of IFNg+ CD8 T cells (G) and TNFa+ CD4 T cells (H) in parental or Slc13a3/ Yumm5.2 tumors, detected by FACS (n = 3). Two-tailed t test, *p < 0.05. (I and J) Tumor growth curves (I), and representative tumor images (J) of Slc13a3+/+ and Slc13a3/ B16-F10 tumors in NSG mice (n = 10–12). All data are presented as mean ± SEM. See also Figure S2.

    Article Snippet: REAGENT or RESOURCE SOURCE IDENTIFIER Antibodies V500 Rat Anti-Mouse CD45 (30-F11) BD Bioscience Cat# 561487; RRID: AB_10697046 FITC Rat Anti-Mouse CD90.2 (53–2.1) BD Bioscience Cat# 553003; RRID: AB_394542 Alexa Fluor 700 Rat Anti-Mouse CD8a (53–6.7) BD Bioscience Cat# 557959;RRID: AB_396959 APC-Cy 7 Rat Anti-Mouse CD4 (GK1.5) BD Bioscience Cat# 552051; RRID: AB_394331 BV786 Rat Anti-Mouse IFNg (XMG1.2) BD Bioscience Cat# 563773; RRID: AB_2738419 PE-Cy 7 Rat Anti-Mouse TNFa (MP6-XT22) BD Bioscience Cat# 557644; RRID: AB_396761 Rabbit Polyclonal Anti-SLC13A3 Thermo Fisher Scientific Cat# PA5-53224; RRID: AB_2647354 Monoclonal Anti-SLC13A3 The Zhiqiang An lab N/A xCT/SLC7A11 Antibody Cell Signaling Technology Cat# 98051; RRID: AB_2800296 Rabbit monoclonal Anti-NRF2 (D1Z9C) Cell Signaling Technology Cat# 12721; RRID: AB_2715528 Rabbit monoclonal Anti-PERK (C33E10) Cell Signaling Technology Cat# 3192; RRID: AB_2095847 Rabbit monoclonal Anti-GAPDH (D16H11) Cell Signaling Technology Cat# 5174; RRID: AB_11129865 Rabbit monoclonal Anti-b-ACTIN (D6A8) Cell Signaling Technology Cat# 8457; RRID: AB_10950489 InVivoPlus Anti-mouse PD-L1 (10F.9G2) Bio X Cell Cat# BE0101; RRID: AB_10949073 InVivoPlus rat IgG2b isotype control (LTF-2) Bio X Cell Cat# BP0090; RRID: AB_1107780 Chemicals, peptides, and recombinant proteins 2-(3-methoxybenzyl) succinic acid AstaTech Inc Cat# W13691 Liproxstatin-1 Cayman Chemical Cat# 17730 4-octyl Itaconate Cayman Chemical Cat# 25374 Itaconate Sigma Aldrich Cat# I29204 Critical commercial assays BODIPY 581/591 C11 Thermo Fisher Scientific Cat# D3861 BODIPY FL C12 Thermo Fisher Scientific Cat# D3822 BioTracker FerroOrange Live Cell Dye Sigma Aldrich Cat# SCT210-35NMOL 7-AAD Staining Solution BD Bioscience Cat# 559925; RRID: AB_2869266 Deposited data Raw Single cell RNA-seq This paper [GEO Database]: [GSE268205] Bulk RNA-seq raw data 1 This paper [GEO Database]: [ GSE268293] Experimental models: Cell lines Mouse cell line: B16-F0 ATCC CRL-6322 Mouse cell line: B16-F10 ATCC CRL-6475 Mouse cell line: Yumm5.2 ATCC CRL-3367 Mouse cell line: MC38 Tanikawa et al.,51 N/A Mouse cell line: MT3 Boj et al.,52 N/A Human cell line: OVCAR3 ATCC HTB-161 Human cell line: A375 ATCC CRL-1619 Human cell line: COLO-679 DSMZ ACC-264 Human cell line: RVH-421 DSMZ ACC-127 Human cell line: OC8 Cui et al.,50 N/A Experimental models: Organisms/strains Mouse: NOD.SCID gc deficient (NSG) The Jackson Laboratory IMSR_JAX:005557 Mouse: C57BL/6J The Jackson Laboratory IMSR_JAX:000664 (Continued on next page) e1 Cancer Cell 42, 1–13.e1–e6, December 9, 2024

    Techniques: Immunopeptidomics, Two Tailed Test